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were analysed immunohistochemically by confocal laser microscopy for the composition
of the the carcinoid endomyocardial tissue components using specific antibodies against
collagen I and III, factor XIIIa, TGF beta and laminin.
Results: The main component of the carcinoid membrane is collagen I, followed by col-
lagen III. The layer is extremely rich with nuclei. - In the subendocardium the laminin sur-
rounds hypertrophic and pycnic myocytes with lipofucein deposits. The regular structure
of normal endomyocardium is disolved, disarray becomes a prominent feature. The carci-
noid membrane itself does not contain laminin, however. – In the borderzone between the
carcinoid membrane and the myocardium a lining of TGF beta positive cells is found reg-
ularly. From there factor XIII positive cells disperse into the surrounding myocytes.
Conclusion: To the best of our knowledge this is the first description that the 2 proteins
TGF beta and factor XIIIa are regular constituants in the carcinoid fibrous plaque in right
ventricular endomyocardium. Both proteins are known to contribute to inflammation and
healing in general. Their presence in the endomyocardium substantiates the „response
to injury hypothesis“ for the pathogenesis of the carcinoid heart.
1087-108 Enhanced Instability of Membranous Type 1 Matrix 
Metalloproteinase in Response to Mechanical Loading 
in Left Ventricular Myocardium
Toshihiro Tsuruda, Lisa C. Costello-Boerrigter, Ondrej Lisy, Brenda K. Huntley, Margaret 
M. Redfield, John C. Burnett, Jr., Mayo Clinic, Rochester, MN
Background The extracellular matrix (ECM) is essential for maintaining the structural
integrity of the heart. Among matrix metalloproteinases (MMPs), membranous type 1
MMP (MT1-MMP) is recognized to be a key enzyme by degrading ECM proteins directly
as well as by activating the other MMPs, including MMP-2. However, it remains to be elu-
cidated if mechanical loading and unloading influence the process of MT1-MMP activity.
We therefore investigated whether mechanical load is responsible for MT1-MMP activity
and consequently affects the induction of MMP-2 activity in ventricular myocardium.
Methods and Results Unloading (UL, n=5) and loading (LO, n=5) of the left ventricle in
dogs were achieved by constriction of the inferior vena cava and by rapid ventricular pac-
ing (180 beats/min) for 10 days, respectively. Although the expression of the active form
(57-kDa) of MT1-MMP in UL and LO did not differ from control (n=6), the inactive form of
MT1-MMP (43-kDa) significantly (p<0.01) increased by 158% in LO, and significantly
(p<0.05) decreased by 55% in UL, assessed by Western blotting. In addition, tissue
inhibitor of MMP (TIMP)-2 significantly (p<0.01) decreased by 56% with the reduction of
zymographic MMP-2 activity in LO.
Conclusion In summary, mechanical loading initiates the autocatalysis of active form
MT1-MMP into inactive form concomitant with TIMP-2 reduction, resulting in decreasing
MMP-2 activity. These in vivo findings suggest that ECM degradation pathway mediated
by MT1-MMP down-regulates in response to mechanical loading to counteract against
the overload. Thus, we speculate the important compensatory biological system of
MMPs/TIMPs for maintaining the adequate ECM circumstance in the development of
heart failure.
1087-133 Assessment of Ventricular Untwisting Recoil Velocity by 
Doppler Tissue Echocardiography: An Index of 
Relaxation Time Constant
Yuichi Notomi, Takahiro Shiota, Zoran B. Popovic, Hirotsugu Yamada, Maureen G. 
Martin-Miklovic, Dimitri G. Deserranno, Don W. Wallick, Neil L. Greenberg, Mario J. 
Garcia, James D. Thomas, Cleveland Clinic Foundation, Cleveland, OH
Background- The rate of recoil of left ventricular (LV) torsion that occurs during isovolu-
mic relaxation, when determined by tagged magnetic resonance imaging (MRI), is a
strong predictor of the relaxation time constant (τ). Doppler tissue echocardiography
(DTE) can detect myocardial velocity directly with higher spatio-temporal resolution than
MRI. We assessed the relationship between τ and LV untwisting velocity (LV-UV) mea-
sured by DTE.
Methods and Results- We obtained micromanometer-recorded LV pressures and DTE
data in 4 anesthetized closed-chest dogs at baseline, during right and left ventricular pac-
ing, and during dobutamine and esmolol infusion (total 21 stages). τ was calculated by
the equation: LVP = P0*e^(-t/τ) + Pb. LV-UV (rad/s) was defined as the difference
between rotational velocities at the basal and apical short-axis levels of the LV. The rota-
tional velocity was calculated from the septal and lateral regional velocity obtained from
the LV short-axis and corrected by the instantaneous LV radius. The LV-UV showed a
strong nonlinear relation with τ (r = 0.80, p < 0.001, see figure). LV-UV showed moderate
correlation with minimum dP/dt (r= 0.41, p = 0.05 by repeated-measures linear regres-
sion).
Conclusions- Ventricular untwisting recoil rate, as determined by DTE using our novel
method, may facilitate measurement of LV pressure decay as an index of relaxation. This
method may provide an estimation of ventricular relaxation in individual patients, allow
serial noninvasive evaluations. 
1087-134 Improved Calcium Homeostasis and Antiarrhythmic 
Effects of a Novel Chimeric Molecule That Inhibits Both 
Type III Phosphodiesterase and L-Type Calcium 
Channel in Failing Hearts
Reza Mazhari, Katayoun Derakhchan, Gregory Hamilton, Marc-Antoine Gillis, Daniel 
Bednarik, Peter Suzdak, Stanley Nattel, Artesian Therapeutics, Gaithersburg, MD, 
Montreal Heart Institute, Montreal, PQ, Canada
Background: Congestive heart failure (CHF) is becoming an increasing contributor to
mortality rate as a function of the aging population. Because of their ability to improve
cardiac performance and symptoms of decompensation, phosphodiesterase inhibitors
(PDEI) have been used in the treatment of patients with severe CHF. However, several tri-
als have shown that PDEIs result in a >25% increase in mortality rate, apparently due to
arrhythmias. We have developed a novel dual-pharmacophore compound (ATI22107)
designed to simultaneously inhibit the cardiac phosphodiesterase PDE3 and the L-type
calcium channel (LCC). We hypothesized that ATI22107 would preserve the beneficial
effects of a pure PDEI, while minimizing deleterious responses through antagonism of
LCC.
Methods: Hemodynamic, echocardiograph, and electrocardiogram data were measured
in anesthetized dogs with tachycardia-induced (220-240 bpm x 5 weeks) CHF. Effects of
graded intravenous doses of ATI22107, and a pure PDEI, milrinone (Mil), on hemody-
namic and arrhythmic indices were compared to those of vehicle control.
Results: Both ATI22107 and Mil resulted in a comparable decline in mean arterial pres-
sure and left ventricular end-diastolic pressure, while heart rate increased <5% in both
groups at all doses. However, Mil infusion resulted in non-sustained ventricular tachycar-
dia (frequency of 173±12 bpm, mean±SEM) at all doses, while none were observed with
ATI22107. ATI22107 produced a dose-dependent increase in the rate of ventricular relax-
ation (-dP/dtmin), with a maximal increase of 120±7% of control, 87% of the maximal
effect of Mil (138±11%). ATI22107 also produced a dose-dependent increase in +dP/
dtmax, ejection fraction, and fractional area shortening, with the maximal increase in con-
tractile indices at the highest dose being only 55 - 70% of the maximal effect of Mil.
Conclusions: ATI22107 improves hemodynamic indices in dogs with CHF, and has
selective lusitropic effects. This novel pattern of hemodynamic action, coupled with a
reduced arrhythmogenic profile, may make ATI22107 a promising agent for CHF therapy,
particularly in patients with a significant component of diastolic dysfunction.
POSTER SESSION
1088 Heart Failure: Treatment
Monday, March 08, 2004, Noon-2:00 p.m.
Morial Convention Center, Hall G
Presentation Hour: 1:00 p.m.-2:00 p.m.
1088-115 Partial Fatty Acid Inhibition by Trimetazidine Improves 
Left Ventricular Function in Patients With Heart Failure 
of Different Etiologies
Gabriele Fragasso, Altin Palloshi, Carmen Silipigni, PierMarco Piatti, Lucilla Monti, 
Emanuela Setola, Giorgio Bassanelli, Chiara Montano, Alberto Margonato, Istituto 
Scientifico/Universita' San Raffaele, Milano, Italy
We assessed whether the addition of the partial fatty acid inhibitor trimetazidine (TMZ) to
standard conventional therapy (CT) in patients (pts) with heart failure, can effectively
improve symptoms, resting left ventricular function and exercise tolerance. Forty-one pts
(37 males, age 64±4 yrs) were randomly allocated in an open label fashion to either CT
(21 pts) or conventional therapy plus TMZ (20 mg tid) (20 pts). All pts underwent 2D-
echocardiography and exercise testing before and at follow up (11±3 months). NYHA
functional class, ejection fraction (EF-%), exercise time (ET-sec) and metabolic units dur-
ing exercise (METS-3.5 ml O2/kg * min) were evaluated. Physicians performing func-
tional tests were blind to patients’ treatment arm. At baseline NYHA class, EF (37±8 vs
38±8), exercise time (411±129 vs 397±143) and METS (7.2±3.1 vs 7.8±2.5) were not dif-
ferent in the TMZ and CT groups, respectively. At follow-up, in the TMZ group 11 pts
improved NYHA class and none worsened, while in CT NYHA class improved only in 2
pts and worsened in other 2. EF significantly increased in TMZ pts compared to CT
(43±9 vs 35±8, p=0.008). Finally, although not significantly, exercise time (414±166 vs
359±137, p=0.25) and METS (8.5±2.7 vs 7.7±1.7, p=0.26) tended to be higher in TMZ
pts. In conclusion, long term TMZ, by shifting the energy substrate preference away from
fatty acid metabolism and toward glucose metabolism, improves left ventricular function
and symptoms in pts with heart failure, regardless of its etiology. The observed TMZ ben-
efit contrasts with the natural history of the disease, as confirmed by the mild but consis-
tent decrease of EF in pts when on CT only. Whether these benefits would translate into
improved survival should be ascertained by a multicenter trial.
